Bone loss in patients with HIV infection

Joint Bone Spine

Volumn 76, Issue 6, 2009, Pages 637-641

  Paccou, Julien ^a,b   Viget, Nathalie ^a   Legrout Gérot, Isabelle ^a   Yazdanpanah, Yazdan ^a   Cortet, Bernard ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b IMPRT IFR114   (France)

Author keywords

Alendronate; Antiretroviral treatment; Fractures; HIV; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; PROTEIN P55; PROTEINASE INHIBITOR; RISEDRONIC ACID; TESTOSTERONE; TUMOR NECROSIS FACTOR RECEPTOR; VITAMIN D;

ANTIVIRAL THERAPY; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; FRAGILITY FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC BONE DISEASE; MORPHOMETRICS; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RISK FACTOR; SHORT SURVEY; SURVIVAL TIME; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; WASTING SYNDROME;

EID: 71249152777     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.10.003     Document Type: Short Survey

References (37)

1. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
2. Gulick R.M., Mellors J.W., Havlir D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337 (1997) 734-739
3. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337 (1997) 725-733
4. Amiel C., Ostertag A., Slama L., et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19 (2004) 402-409
5. Tebas P., Powderly W.G., Claxton S., et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14 (2000) F63-F67
6. Carr A., Miller J., Eisman J.A., et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15 2 (2001) 703-709
7. Madeddu G., Spanu A., Solinas P., et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48 (2004) 39-48
8. Yin M., Dobkin J., Brudney K., et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 16 (2005) 1345-1352
9. Brown T.T., and Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20 (2006) 2165-2174
10. Paton N.I., Macallan D.C., Griffin G.E., et al. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 61 (1997) 30-32
11. Mondy K., Yarasheski K., Powderly W.G., et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36 (2003) 482-490
12. Nolan D., Upton R., McKinnon E., et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15 (2001) 1275-1280
13. Dolan S.E., Kanter J.R., and Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 91 (2006) 2938-2945
14. Fernandez Rivera J., Garcia R., Lozano F., et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients HIV. Clin Trials 4 (2003) 337-346
15. Tebas P., Yarasheski K., Henry K., et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 20 (2004) 589-594
16. Gallant J.E., Staszewski S., Pozniak A.L., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
17. Aukrust P., Haug C.J., Ueland T., et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84 (1999) 145-150
18. Fairfield W.P., Finkelstein J.S., Klibanski A., et al. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 86 (2001) 2020-2026
19. Serrano S., Marinoso M.L., Soriano J.C., et al. Bone remodelling in human immunodeficiency virus -1 infected patient. A histomorphometric study. Bone 16 (1995) 185-191
20. Hernandez Quero J., Ortego Centeno N., Munoz-Torres M., et al. Alterations in bone turnover in HIV-positive patients. Infection 21 (1993) 220-222
21. Haug C., Müller F., Aukrust P., et al. Subnormal serum concentration of 1, 25-vitamin D3 in HIV infection: correlation with degree of immunodeficiency and survival. J Infect Dis 169 (1994) 889-893
22. Lange U., Teichmann J., Strunk J., et al. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16 (2005) 1999-2004
23. Earle K.E., Seneviratne T., Shaker J., et al. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 19 (2004) 714-721
24. Parsonage M.J., Wilkins E.G., Snowden N., et al. The development of hypophosphatemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 6 (2005) 341-346
25. Guaraldi G., Ventura P., Albuzza M., et al. Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 15 (2001) 137-138
26. Stephens E.A., Das R., Madge S., et al. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 13 (1999) 2605-2606
27. Prior J., Burdge D., Maan E., et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 18 10 (2007) 1345-1353
28. Kopicko J.J., Momodu I., Adedokun A., et al. Characteristics of HIV-infected men with low serum testosterone levels. Int J STD AIDS 10 (1999) 817-820
29. Rietschel P., Corcoran C., and Stanley T. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infections who were receiving highly active antiretroviral therapy. Clin Infect Dis 31 (2000) 1240-1244
30. Haug C.J., Aukrust P., Lien E., et al. Disseminated Mycobacterium avium complex infection in AIDS: immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin D. J Infect Dis 173 (1996) 259-262
31. Haug C.J., Aukrust P., Haug E., et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in HIV-infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 83 (1998) 3832-3838
32. Fakruddin M, Yin M, Laurence J. Pathophysiologic correlates of RANKL deregulation in HIV infection and its therapy [abstract]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
33. McComsey G.A., Huang J.S., Woolley I.J., et al. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic Ill) 3 (2004) 86-91
34. Lin D., and Rieder M.J. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev (2007) CD005645
35. Mondy K., Powderly W.G., Claxton S.A., et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 38 (2005) 426-431
36. Guaraldi G., Orlando G., Madeddu G., et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 5 (2004) 269-277
37. Negredo E., Martinez-Lopez E., Paredes R., et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 19 (2005) 343-345